Key Recommendations: 2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease

Select Content Type
Briefs
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
ESC thmbnl
Detail Image
ESC mob det
Book Detail
Actions
Download in App
Countries of release
Ghana
India
Kenya
Malawi
Nigeria
UAE
Zambia
IS_Ebsco
false
Description

The 2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease, developed by the European Society of Cardiology (ESC) in collaboration with the European Renal Association (ERA), are the first guidelines dedicated to the management of cardiovascular disease (CVD) and chronic kidney disease (CKD). CKD is closely associated with several cardiovascular conditions, including coronary artery disease (CAD), heart failure (HF), arrhythmias, stroke, peripheral arterial disease (PAD), and sudden cardiac death (SCD). These guidelines emphasize an integrated cardiorenal approach focused on early CKD detection, cardiovascular risk reduction, and individualized treatment based on kidney function. 

Click the button to explore the key recommendations from the guideline in detail.

Published Date